 | • レポートコード：QY2207C3838 • 出版社/出版日：QYResearch / 2022年7月11日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界の地図状萎縮の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に地図状萎縮の世界市場のxxx％を占める「60歳以上」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「後期（フェーズIII）」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の地図状萎縮の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの地図状萎縮市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの地図状萎縮市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 地図状萎縮のグローバル主要メーカーには、Apellis Pharmaceuticals、Iveric Bio、Alkeus Pharmaceuticals、Hemera Biosciences、Allegro Ophthalmics、Stealth BioTherapeutics、Gyroscope Therapeutics、Regenerative Patch Technologies、Roche、Gensight Biologics、NGM Biopharmaceuticals、AstraZeneca、Lineage Cell Therapeutics、Allerganなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 地図状萎縮市場は、種類と用途によって区分されます。世界の地図状萎縮市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 60歳以上、75歳以上 【用途別セグメント】 後期（フェーズIII）、フェーズII、フェーズI、前臨床段階 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 地図状萎縮製品概要 - 種類別市場（60歳以上、75歳以上） - 用途別市場（後期（フェーズIII）、フェーズII、フェーズI、前臨床段階） - 調査の目的 ・エグゼクティブサマリー - 世界の地図状萎縮販売量予測2017-2028 - 世界の地図状萎縮売上予測2017-2028 - 地図状萎縮の地域別販売量 - 地図状萎縮の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別地図状萎縮販売量 - 主要メーカー別地図状萎縮売上 - 主要メーカー別地図状萎縮価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（60歳以上、75歳以上） - 地図状萎縮の種類別販売量 - 地図状萎縮の種類別売上 - 地図状萎縮の種類別価格 ・用途別市場規模（後期（フェーズIII）、フェーズII、フェーズI、前臨床段階） - 地図状萎縮の用途別販売量 - 地図状萎縮の用途別売上 - 地図状萎縮の用途別価格 ・北米市場 - 北米の地図状萎縮市場規模（種類別、用途別） - 主要国別の地図状萎縮市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの地図状萎縮市場規模（種類別、用途別） - 主要国別の地図状萎縮市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の地図状萎縮市場規模（種類別、用途別） - 主要国別の地図状萎縮市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の地図状萎縮市場規模（種類別、用途別） - 主要国別の地図状萎縮市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの地図状萎縮市場規模（種類別、用途別） - 主要国別の地図状萎縮市場規模（トルコ、サウジアラビア） ・企業情報 Apellis Pharmaceuticals、Iveric Bio、Alkeus Pharmaceuticals、Hemera Biosciences、Allegro Ophthalmics、Stealth BioTherapeutics、Gyroscope Therapeutics、Regenerative Patch Technologies、Roche、Gensight Biologics、NGM Biopharmaceuticals、AstraZeneca、Lineage Cell Therapeutics、Allergan ・産業チェーン及び販売チャネル分析 - 地図状萎縮の産業チェーン分析 - 地図状萎縮の原材料 - 地図状萎縮の生産プロセス - 地図状萎縮の販売及びマーケティング - 地図状萎縮の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 地図状萎縮の産業動向 - 地図状萎縮のマーケットドライバー - 地図状萎縮の課題 - 地図状萎縮の阻害要因 ・主な調査結果 |
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that causes a continuous progressive degeneration of the macula. The condition is characterized by widespread atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. It typically starts in the perifoveal region and develops to the fovea over time and causing central scotomas and permanent vision loss. Various drugs and treatments are under evaluation.
Market Analysis and Insights: Global Geographic Atrophy Market
The global Geographic Atrophy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Above 60 Years accounting for % of the Geographic Atrophy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Late-stage (Phase III) segment is altered to an % CAGR throughout this forecast period.
China Geographic Atrophy market size is valued at US$ million in 2021, while the North America and Europe Geographic Atrophy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Geographic Atrophy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Geographic Atrophy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Geographic Atrophy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Geographic Atrophy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Geographic Atrophy market.
Global Geographic Atrophy Scope and Market Size
Geographic Atrophy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Geographic Atrophy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Above 60 Years
Above 75 Years
Segment by Application
Late-stage (Phase III)
Phase II
Phase I
Pre-clinical stage
By Company
Apellis Pharmaceuticals
Iveric Bio
Alkeus Pharmaceuticals
Hemera Biosciences
Allegro Ophthalmics
Stealth BioTherapeutics
Gyroscope Therapeutics
Regenerative Patch Technologies
Roche
Gensight Biologics
NGM Biopharmaceuticals
AstraZeneca
Lineage Cell Therapeutics
Allergan
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Geographic Atrophy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Above 60 Years
1.2.3 Above 75 Years
1.3 Market by Application
1.3.1 Global Geographic Atrophy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Late-stage (Phase III)
1.3.3 Phase II
1.3.4 Phase I
1.3.5 Pre-clinical stage
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Geographic Atrophy Market Perspective (2017-2028)
2.2 Geographic Atrophy Growth Trends by Region
2.2.1 Geographic Atrophy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Geographic Atrophy Historic Market Size by Region (2017-2022)
2.2.3 Geographic Atrophy Forecasted Market Size by Region (2023-2028)
2.3 Geographic Atrophy Market Dynamics
2.3.1 Geographic Atrophy Industry Trends
2.3.2 Geographic Atrophy Market Drivers
2.3.3 Geographic Atrophy Market Challenges
2.3.4 Geographic Atrophy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Geographic Atrophy Players by Revenue
3.1.1 Global Top Geographic Atrophy Players by Revenue (2017-2022)
3.1.2 Global Geographic Atrophy Revenue Market Share by Players (2017-2022)
3.2 Global Geographic Atrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Geographic Atrophy Revenue
3.4 Global Geographic Atrophy Market Concentration Ratio
3.4.1 Global Geographic Atrophy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Geographic Atrophy Revenue in 2021
3.5 Geographic Atrophy Key Players Head office and Area Served
3.6 Key Players Geographic Atrophy Product Solution and Service
3.7 Date of Enter into Geographic Atrophy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Geographic Atrophy Breakdown Data by Type
4.1 Global Geographic Atrophy Historic Market Size by Type (2017-2022)
4.2 Global Geographic Atrophy Forecasted Market Size by Type (2023-2028)
5 Geographic Atrophy Breakdown Data by Application
5.1 Global Geographic Atrophy Historic Market Size by Application (2017-2022)
5.2 Global Geographic Atrophy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Geographic Atrophy Market Size (2017-2028)
6.2 North America Geographic Atrophy Market Size by Type
6.2.1 North America Geographic Atrophy Market Size by Type (2017-2022)
6.2.2 North America Geographic Atrophy Market Size by Type (2023-2028)
6.2.3 North America Geographic Atrophy Market Share by Type (2017-2028)
6.3 North America Geographic Atrophy Market Size by Application
6.3.1 North America Geographic Atrophy Market Size by Application (2017-2022)
6.3.2 North America Geographic Atrophy Market Size by Application (2023-2028)
6.3.3 North America Geographic Atrophy Market Share by Application (2017-2028)
6.4 North America Geographic Atrophy Market Size by Country
6.4.1 North America Geographic Atrophy Market Size by Country (2017-2022)
6.4.2 North America Geographic Atrophy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Geographic Atrophy Market Size (2017-2028)
7.2 Europe Geographic Atrophy Market Size by Type
7.2.1 Europe Geographic Atrophy Market Size by Type (2017-2022)
7.2.2 Europe Geographic Atrophy Market Size by Type (2023-2028)
7.2.3 Europe Geographic Atrophy Market Share by Type (2017-2028)
7.3 Europe Geographic Atrophy Market Size by Application
7.3.1 Europe Geographic Atrophy Market Size by Application (2017-2022)
7.3.2 Europe Geographic Atrophy Market Size by Application (2023-2028)
7.3.3 Europe Geographic Atrophy Market Share by Application (2017-2028)
7.4 Europe Geographic Atrophy Market Size by Country
7.4.1 Europe Geographic Atrophy Market Size by Country (2017-2022)
7.4.2 Europe Geographic Atrophy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Geographic Atrophy Market Size (2017-2028)
8.2 Asia-Pacific Geographic Atrophy Market Size by Type
8.2.1 Asia-Pacific Geographic Atrophy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Geographic Atrophy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Geographic Atrophy Market Share by Type (2017-2028)
8.3 Asia-Pacific Geographic Atrophy Market Size by Application
8.3.1 Asia-Pacific Geographic Atrophy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Geographic Atrophy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Geographic Atrophy Market Share by Application (2017-2028)
8.4 Asia-Pacific Geographic Atrophy Market Size by Region
8.4.1 Asia-Pacific Geographic Atrophy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Geographic Atrophy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Geographic Atrophy Market Size (2017-2028)
9.2 Latin America Geographic Atrophy Market Size by Type
9.2.1 Latin America Geographic Atrophy Market Size by Type (2017-2022)
9.2.2 Latin America Geographic Atrophy Market Size by Type (2023-2028)
9.2.3 Latin America Geographic Atrophy Market Share by Type (2017-2028)
9.3 Latin America Geographic Atrophy Market Size by Application
9.3.1 Latin America Geographic Atrophy Market Size by Application (2017-2022)
9.3.2 Latin America Geographic Atrophy Market Size by Application (2023-2028)
9.3.3 Latin America Geographic Atrophy Market Share by Application (2017-2028)
9.4 Latin America Geographic Atrophy Market Size by Country
9.4.1 Latin America Geographic Atrophy Market Size by Country (2017-2022)
9.4.2 Latin America Geographic Atrophy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Geographic Atrophy Market Size (2017-2028)
10.2 Middle East & Africa Geographic Atrophy Market Size by Type
10.2.1 Middle East & Africa Geographic Atrophy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Geographic Atrophy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Geographic Atrophy Market Share by Type (2017-2028)
10.3 Middle East & Africa Geographic Atrophy Market Size by Application
10.3.1 Middle East & Africa Geographic Atrophy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Geographic Atrophy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Geographic Atrophy Market Share by Application (2017-2028)
10.4 Middle East & Africa Geographic Atrophy Market Size by Country
10.4.1 Middle East & Africa Geographic Atrophy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Geographic Atrophy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Apellis Pharmaceuticals
11.1.1 Apellis Pharmaceuticals Company Details
11.1.2 Apellis Pharmaceuticals Business Overview
11.1.3 Apellis Pharmaceuticals Geographic Atrophy Introduction
11.1.4 Apellis Pharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.1.5 Apellis Pharmaceuticals Recent Developments
11.2 Iveric Bio
11.2.1 Iveric Bio Company Details
11.2.2 Iveric Bio Business Overview
11.2.3 Iveric Bio Geographic Atrophy Introduction
11.2.4 Iveric Bio Revenue in Geographic Atrophy Business (2017-2022)
11.2.5 Iveric Bio Recent Developments
11.3 Alkeus Pharmaceuticals
11.3.1 Alkeus Pharmaceuticals Company Details
11.3.2 Alkeus Pharmaceuticals Business Overview
11.3.3 Alkeus Pharmaceuticals Geographic Atrophy Introduction
11.3.4 Alkeus Pharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.3.5 Alkeus Pharmaceuticals Recent Developments
11.4 Hemera Biosciences
11.4.1 Hemera Biosciences Company Details
11.4.2 Hemera Biosciences Business Overview
11.4.3 Hemera Biosciences Geographic Atrophy Introduction
11.4.4 Hemera Biosciences Revenue in Geographic Atrophy Business (2017-2022)
11.4.5 Hemera Biosciences Recent Developments
11.5 Allegro Ophthalmics
11.5.1 Allegro Ophthalmics Company Details
11.5.2 Allegro Ophthalmics Business Overview
11.5.3 Allegro Ophthalmics Geographic Atrophy Introduction
11.5.4 Allegro Ophthalmics Revenue in Geographic Atrophy Business (2017-2022)
11.5.5 Allegro Ophthalmics Recent Developments
11.6 Stealth BioTherapeutics
11.6.1 Stealth BioTherapeutics Company Details
11.6.2 Stealth BioTherapeutics Business Overview
11.6.3 Stealth BioTherapeutics Geographic Atrophy Introduction
11.6.4 Stealth BioTherapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.6.5 Stealth BioTherapeutics Recent Developments
11.7 Gyroscope Therapeutics
11.7.1 Gyroscope Therapeutics Company Details
11.7.2 Gyroscope Therapeutics Business Overview
11.7.3 Gyroscope Therapeutics Geographic Atrophy Introduction
11.7.4 Gyroscope Therapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.7.5 Gyroscope Therapeutics Recent Developments
11.8 Regenerative Patch Technologies
11.8.1 Regenerative Patch Technologies Company Details
11.8.2 Regenerative Patch Technologies Business Overview
11.8.3 Regenerative Patch Technologies Geographic Atrophy Introduction
11.8.4 Regenerative Patch Technologies Revenue in Geographic Atrophy Business (2017-2022)
11.8.5 Regenerative Patch Technologies Recent Developments
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Geographic Atrophy Introduction
11.9.4 Roche Revenue in Geographic Atrophy Business (2017-2022)
11.9.5 Roche Recent Developments
11.10 Gensight Biologics
11.10.1 Gensight Biologics Company Details
11.10.2 Gensight Biologics Business Overview
11.10.3 Gensight Biologics Geographic Atrophy Introduction
11.10.4 Gensight Biologics Revenue in Geographic Atrophy Business (2017-2022)
11.10.5 Gensight Biologics Recent Developments
11.11 NGM Biopharmaceuticals
11.11.1 NGM Biopharmaceuticals Company Details
11.11.2 NGM Biopharmaceuticals Business Overview
11.11.3 NGM Biopharmaceuticals Geographic Atrophy Introduction
11.11.4 NGM Biopharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.11.5 NGM Biopharmaceuticals Recent Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Geographic Atrophy Introduction
11.12.4 AstraZeneca Revenue in Geographic Atrophy Business (2017-2022)
11.12.5 AstraZeneca Recent Developments
11.13 Lineage Cell Therapeutics
11.13.1 Lineage Cell Therapeutics Company Details
11.13.2 Lineage Cell Therapeutics Business Overview
11.13.3 Lineage Cell Therapeutics Geographic Atrophy Introduction
11.13.4 Lineage Cell Therapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.13.5 Lineage Cell Therapeutics Recent Developments
11.14 Allergan
11.14.1 Allergan Company Details
11.14.2 Allergan Business Overview
11.14.3 Allergan Geographic Atrophy Introduction
11.14.4 Allergan Revenue in Geographic Atrophy Business (2017-2022)
11.14.5 Allergan Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer